"At Minnesota Oncology, we are dedicated to providing compassionate care for various types of cancer and blood disorders in 12 convenient Twin Cities metro locations as well as several satellite locations. Our mission is to combine the strength of hope with the power of science, one patient at a time."

During the past decade, Minnesota Oncology Hematology PA-Maplewood conducted 162 clinical trials. In the 10-year time frame, 162 clinical trials started and 218 clinical trials were completed, i.e. on average, 134.6% percent of trials that started reached the finish line to date. In the past 5 years, 44 clinical trials started and 67 clinical trials were completed. i.e. 152.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Minnesota Oncology Hematology PA-Maplewood" #1 sponsor was "National Cancer Institute (NCI)" with 165 trials, followed by "Alliance for Clinical Trials in Oncology" with 112 trials sponsored, "SWOG Cancer Research Network" with 58 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 29 trials sponsored and "Eastern Cooperative Oncology Group" with 29 trials sponsored. Other sponsors include 67 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Minnesota Oncology Hematology PA-Maplewood" #1 collaborator was "National Cancer Institute (NCI)" with 288 trials as a collaborator, "NRG Oncology" with 43 trials as a collaborator, "Cancer and Leukemia Group B" with 13 trials as a collaborator, "NCIC Clinical Trials Group" with 12 trials as a collaborator and "SWOG Cancer Research Network" with 12 trials as a collaborator. Other collaborators include 82 different institutions and companies that were collaborators in the rest 52 trials.

According to Clinical.Site data, the most researched conditions in "Minnesota Oncology Hematology PA-Maplewood" are "Breast Cancer" (37 trials), "Lung Cancer" (19 trials), "Lymphoma" (16 trials), "Unspecified Adult Solid Tumor, Protocol Specific" (14 trials) and "Colorectal Cancer" (12 trials). Many other conditions were trialed in "Minnesota Oncology Hematology PA-Maplewood" in a lesser frequency.

Most popular intervention types in "Minnesota Oncology Hematology PA-Maplewood" are "Drug" (372 trials), "Other" (246 trials), "Biological" (178 trials), "Procedure" (94 trials) and "Radiation" (76 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (108 trials), "Quality-of-Life Assessment" (92 trials), "Questionnaire Administration" (56 trials), "Paclitaxel" (44 trials) and "Carboplatin" (37 trials). Other intervention names were less common.

The vast majority of trials in "Minnesota Oncology Hematology PA-Maplewood" are 368 trials for "All" genders, 73 trials for "Female" genders and 21 trials for "Male" genders.

Currently, there are NaN active trials in "Minnesota Oncology Hematology PA-Maplewood". undefined are not yet recruiting, 73 are recruiting, 145 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 199 completed trials in Minnesota Oncology Hematology PA-Maplewood, 7 suspended trials, and 30 terminated clinical trials to date.

Out of the total trials that were conducted in Minnesota Oncology Hematology PA-Maplewood, 15 "Phase 1" clinical trials were conducted, 228 "Phase 2" clinical trials and 207 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 14 trials that are defined as “Not Applicable".